Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Mikael Kofod-Hansen

Jens Breinholt

Ida Hilden

Per Sauerberg

Thomas Kruse

Thomas Hoeg-Jensen

Henning Thoegersen

Carsten Behrens

Miroslav Havranek

Berit Olsen Krogh

Helle Heibroch Petersen

Ivan Snajdr

Martin Werner Borchsenius Muenzel

Ladislav Droz

Vladislav Kotek

Milan Stengl

Hana Drusanova

Zuzana Drobnakova

Vojtech Balsanek

Lars Christian Petersen

Jakob Ewald Rasmussen

Bernd Peschke

Nils Langeland Johansen

Henrik Oestergaard

Henning Ralf Stennicke

Jens Buchardt

Soeren Oestergaard

Marianne Hjortnes Kjalke

Jakob Ewald

Emiliano Clo

Henning THØGERSEN

Henrik Sune Ramirez-Andersen

Magali A Zundel

Jens Jacob Hansen

Emiliano ClÓ

Henrik Sune RAMÍREZ-Andersen

Thomas HØEG-Jensen

Zuzana DROBNÁKOVÁ

Miroslav HAVRÁNEK

Hana VÁNOVÁ

Martin Werner Borchsenius MÜNZEL

Vojtech BALSÁNEK

Henrik ØStergaard

Eva H Norling Olsen

Thomas R Barnett

Tony Pusateri

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates.

Glucose-sensitive albumin-binding derivatives

The invention relates to protein conjugates and in particular conjugates of more than two protein or polypeptides. The compounds include a trivalent linker moiety that enables efficient production of desired products.

Protein conjugates

The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.

Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)

This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X&#x2014;R2, and wherein 'X' is a mono- to multiatomic linker and where Rand R, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I'), which is: R1&#x2032;-X&#x2032;&#x2014;R2&#x2032;, in which either the moeities R1&#x2032; or R2&#x2032; or X&#x2032; carry a drug that is covalently attached to the diboron compound.

Described are procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing procoagulant proteins; polynucleotides that encode fusion proteins and cells that expresses them. Furthermore, described are procoagulant proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with such procoagulant proteins.

Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets

The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI&#x3b1;, even where the concentration of TFPI is abnormally elevated.

Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.

Selective modification of proteins

Growing community of inventors

Broenshoej, Denmark

Mikael Kofod-Hansen